INNOVADERM CRO IS NOW INDERO.

Join Indero at the AID’s Dermatology Summit in San Francisco!

Indero

Indero

Team of Experts

Author picture

Once again, Indero is sponsoring Advancing Innovation in Dermatology (AID) and will be exhibiting at the Dermatology Summit in San Francisco on January 11, 2026, taking place at the Hyatt Regency in San Francisco.

This summit is an excellent opportunity to connect with industry leaders, explore innovative solutions, and discuss the future of dermatology research.

Our team will be available throughout the event to share insights on how Indero supports sponsors in achieving their goals through expertise, collaboration, and operational excellence.

Connect with Dr. Jasmina JankicevicVincent Scamacca, and Richard Cote while in San Francisco!

 

SHARE THIS POST

Subscribe to our newsletter.

Do not miss out on valuable insights and research updates. Join our scientific community today!

This field is for validation purposes and should be left unchanged.

Jeff Smith

Chef de la direction

Jeff Smith, Chef de la direction d’Indero Recherches, apporte près de 30 ans d’expérience dans l’industrie pharmaceutique et CRO, s’étant distingué par son leadership exceptionnel, sa vision stratégique et son innovation. L’expertise de Jeff couvre des opérations mondiales, la gestion de la croissance, ainsi que la promotion d’une culture d’entreprise collaborative. Ses atouts en matière de création de valeur, de gestion des partenaires et d’opérations CRO ont toujours contribué au succès dans ses fonctions précédentes. Sous la direction de Jeff, Indero continue d’étendre ses capacités, faisant progresser les connaissances médicales et les nouvelles thérapies en dermatologie et en rhumatologie.

Revolutionize Your Topical Trials

Efficacy insights in days, not months.

 Indero’s Early Phase 1 model enables sponsors to initiate topical studies that detect early pharmacodynamic signals much sooner than traditional phase 1, using microdosing and transcriptomic analysis. This approach reduces preclinical requirements, shortens study duration from 8–12 weeks to ≤3 days, and lowers costs, helping teams make informed go/no-go decisions faster.